Abstracts tagged "methotrexate (MTX)"

Abstract Number: 218 • 2018 ACR/ARHP Annual Meeting
Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Rishi J. Desai³, Angela Tong¹ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Treatment with tumor necrosis factor inhibitor (TNFi) with methotrexate or triple therapy (MTX, sulfasalazine, and sulfasalazine) is considered in patients with rheumatoid arthritis (RA)…
Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting
Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
Xavier M Teitsma¹, Johannes W. G. Jacobs², Pascal HP de Jong³, JMW Hazes³, Angelique EAM Weel^3,4, Paco MJ Welsing¹, Attila Pethö-Schramm⁵, Michelle EA Borm⁶, Jacob van Laar¹, Johannes W. J. Bijlsma⁷ and Floris PJG Lafeber⁸, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁴Rheumatology, Maastad Hospital, Rotterdam, Netherlands, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Roche Nederland BV, Woerden, Netherlands, ⁷Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁸Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…
Abstract Number: 2954 • 2018 ACR/ARHP Annual Meeting
Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Angela Tong¹, Rishi J. Desai³ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: While efficacy of triple therapy [methotrexate (MTX), sulfasalazine (HCQ), and sulfasalazine (SSZ)] and TNF inhibitor (TNFi) plus MTX was similar in a previous clinical…
Abstract Number: 428 • 2018 ACR/ARHP Annual Meeting
Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; Results from a Randomised Controlled Phase III Trial of Treatment Effectiveness
Sarah R. Kingsbury¹, Puvan Tharmanathan², Ada Keding², Belen Corbacho², Fiona E Watt³, David L Scott⁴, Edward Roddy⁵, Fraser Birrell⁶, Nigel K Arden⁷, Catherine Arundel², Sarah Ronaldson², Lema Vernon⁸, Catherine Hewitt², Michael Doherty⁹, David Torgerson² and Philip G. Conaghan¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, United Kingdom, Leeds, United Kingdom, ²York Trials Unit, University of York, York, United Kingdom, ³Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁴Department of Rheumatology, King's College London, London, United Kingdom, ⁵Staffordshire and Stoke on Trent Partnership NHS Foundation Trust, Newcastle Under Lyme, United Kingdom, ⁶Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, ⁷Arthritis Research UK Centre for Sports, Exercise and Osteoarthritis, University of Oxford, Oxford, United Kingdom, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹The University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Current treatments for osteoarthritis (OA) are severely limited. Synovitis is prevalent in OA and is associated with pain. The slow-acting anti-rheumatic drug methotrexate (MTX)…
Abstract Number: 1531 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Show Similar Retention When Used with and without Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Tofacitinib (TOFA), a targeted synthetic DMARD has recently appeared on the Canadian market. It is an oral agent, targeting the JAK 1 and JAK…
Abstract Number: 2984 • 2018 ACR/ARHP Annual Meeting
Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett^1,2, Orit Schieir³, Marie-France Valois⁴, Carol Hitchon⁵, Louis Bessette⁶, Gilles Boire⁷, Carter Thorne⁸, Janet E. Pope⁹, Vivian P. Bykerk¹⁰, Edward C. Keystone¹¹, Diane Tin¹² and Glen Hazlewood¹³, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³McGill University, Montreal, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁷Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Toronto, Newmarket, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Implementation of RA guidelines have improved remission outcomes in RA; nevertheless 45% of early RA participants do not achieve remission in the first year.…
Abstract Number: 477 • 2018 ACR/ARHP Annual Meeting
Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
Takayuki Kishi^1,2, Jesse Wilkerson³, Marjo Smith³, Nastaran Bayat¹, Michael Henrickson⁴, Bianca Lang⁵, Murray Passo⁶, Frederick W. Miller¹, Michael Ward⁷ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³Social & Scientific Systems, Inc., Durham, NC, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁶Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Daily oral prednisone has been the main therapy in juvenile dermatomyositis (JDM), and combination therapy with methotrexate (MTX) introduced soon after diagnosis has been…
Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting
Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
Leonieke van Mens¹, Jet de Jong², Inka Fluri¹, Marleen van de Sande³, Michael Nurmohamed⁴, M.R. Kok⁵, Arno van Kuijk⁶ and Dominique Baeten², ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands
Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…
Abstract Number: 566 • 2018 ACR/ARHP Annual Meeting
Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases
Thierry Dervieux¹, Kelley Brady¹, Deborah Stimson¹, Ying Qu¹, Tyler O'Malley¹, Robert Apilado¹, Smitha Reddy², Puja Chitkara³, John Conklin¹, Roberta Alexander¹ and Claudia Ibarra¹, ¹Exagen Diagnostics, Inc., Vista, CA, ²Arthritis Care and Research Center, San Diego, CA, ³Center for Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: The red blood cell (RBC) Methotrexate (MTX) polyglutamate (MTXPG3) assay is a helpful therapeutic drug monitoring (TDM) tool in autoimmune rheumatic diseases. Our objective…
Abstract Number: 1859 • 2018 ACR/ARHP Annual Meeting
The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Alexander Platzer², Farideh Alasti², Paul Studenic³, Maresa Grundhuber⁴, Sascha Swiniarski⁴, Stephan Blüml², Helmuth Haslacher⁵, Josef S. Smolen⁶ and Günter Steiner¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ⁵Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). Lately we showed that the determination…
Abstract Number: 572 • 2018 ACR/ARHP Annual Meeting
Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Biologic therapy targeting TNF have consistently demonstrated better efficacy and effectiveness when combined with a conventional synthetic DMARD (csDMARD), most frequently methotrexate. Although pre-clinical…
Abstract Number: 2138 • 2018 ACR/ARHP Annual Meeting
Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
Brian Ung¹, Dionne Hines², Sandhya Mehta¹, Corey Pelletier¹, Xin Wang² and Rolin Wade², ¹Celgene Corporation, Summit, NJ, ²IQVIA, Durham, NC
Background/Purpose: Methotrexate (MTX) is commonly used to treat psoriatic arthritis (PsA), yet data supporting its effectiveness in PsA are limited. This analysis describes real-world dosing,…
Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
Stanley Cohen¹, Boulos Haraoui², Jeffrey R. Curtis³, Timothy Smith⁴, John Woolcott⁵, David Gruben⁶, Christopher W Murray⁵, Noriko Iikuni⁴, Andrew Koenig⁵ and James Harnett⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…
Abstract Number: 2348 • 2018 ACR/ARHP Annual Meeting
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Maria A. Lopez-Olivo¹, Jude K. A. des Bordes¹, Gregory Pratt² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of…
Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
Cristina Ruiz-Romero¹, Florencia Picchi², Lucia González², Rebecca Hands³, Valentina Calamia², Patricia Fernández⁴, Maria Camacho², Rocío Paz², Conrad Bessant⁵, Costantino Pitzalis³ and Francisco J Blanco⁶, ¹Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁴Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁵School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].